Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Short Interest Update

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the target of a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 369,209 shares, an increase of 92.0% from the December 15th total of 192,269 shares. Approximately 9.1% of the company’s shares are sold short. Based on an average daily volume of 98,361 shares, the short-interest ratio is currently 3.8 days. Based on an average daily volume of 98,361 shares, the short-interest ratio is currently 3.8 days. Approximately 9.1% of the company’s shares are sold short.

Institutional Trading of Coeptis Therapeutics

A hedge fund recently bought a new stake in Coeptis Therapeutics stock. Yorkville Advisors Global LP purchased a new stake in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 8,000 shares of the company’s stock, valued at approximately $140,000. Coeptis Therapeutics accounts for about 0.0% of Yorkville Advisors Global LP’s holdings, making the stock its 24th largest holding. Yorkville Advisors Global LP owned approximately 0.17% of Coeptis Therapeutics at the end of the most recent reporting period. 13.88% of the stock is currently owned by institutional investors and hedge funds.

Coeptis Therapeutics Stock Down 7.2%

Shares of NASDAQ COEP opened at $12.67 on Friday. The stock has a market capitalization of $67.66 million, a PE ratio of -4.43 and a beta of -0.50. The company has a quick ratio of 2.21, a current ratio of 2.21 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $15.34 and a 200-day moving average of $13.87. Coeptis Therapeutics has a 52-week low of $6.26 and a 52-week high of $21.41.

Coeptis Therapeutics (NASDAQ:COEP) last issued its earnings results on Thursday, November 13th. The company reported ($0.58) earnings per share for the quarter. The company had revenue of $0.24 million during the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.